Cynapsus Therapeutics Reports 2012 Financial Results and Highlights Key Developments
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 04/26/13 -- Cynapsus Therapeutics Inc. (TSX VENTURE: CTH), a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease, today announced its results for the fourth quarter and fiscal year ended December 31, 2012. Unless specified otherwise, all amounts are in Canadian dollars.
"2012 was a transformative year for Cynapsus with the achievement of multiple significant milestones. In particular, the year was highlighted by the completion of two human clinical trials for APL-130277, the announcement of a US$947,925 research grant from The Michael J. Fox Foundation (MJFF), a notice of allowance from the US Patent Office, and the announcement of the $6 to 8 million short form prospectus financing that was completed early this year," said Anthony Giovinazzo, President and Chief Executive Officer of Cynapsus. "As previously announced, in March 2013 the Company successfully raised $7.3 million, converted $4 million of debt to equity, and completed a 10:1 share consolidation. We are now focused on the completion of the MJFF sponsored CTH103 study, as well as preparations for an Investigational New Drug Application to the US FDA for a clinical Bioequivalence study. The BEQ study is the next critical de-risking milestone that we believe will drive significant shareholder value."
Financial Highlights
Operational Highlights
The following achievements were made during the year:
About Cynapsus Therapeutics
Cynapsus is a specialty pharmaceutical company developing the only non-injectable (i.e. sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease. Over one million people in the U.S. and an estimated 5 million people globally suffer from Parkinson's disease. Parkinson's disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. Based on a recent study and the results of the Company's Global 500 Neurologists Survey, it is estimated that between 25 percent and 50 percent of patients experience "off" episodes in which they have impaired movement or speaking capabilities. Current medications only control the disease's symptoms, and most drugs become less effective over time as the disease progresses.
Cynapsus' drug candidate, APL-130277, is an easy-to-administer, fast-acting reformulation of apomorphine, which is approved in an injection formulation to rescue patients from "off" episodes. Cynapsus is focused on maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application expected to be submitted in 2015. Cynapsus anticipates a trade sale or out-licensing to an appropriate global pharmaceutical partner before such an application is submitted.
More information about Cynapsus (TSX VENTURE: CTH) is available at and at the System for Electronic Document Analysis and Retrieval (SEDAR) at .
Forward Looking Statements
This announcement contains "forward-looking statements" within the meaning of applicable Canadian securities legislation. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Cynapsus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks and uncertainties relating to Cynapsus' business disclosed under the heading "Risk Factors" in its Annual Information Form filed on November 1, 2012 and its other filings with the various Canadian securities regulators which are available online at . Although Cynapsus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cynapsus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.
Contacts:
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
Cynapsus Therapeutics
Andrew Williams
COO & CFO
(416) 703-2449 x253
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.04.2013 - 15:50 Uhr
Sprache: Deutsch
News-ID 1220902
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Alternative
Anmerkungen:
Diese Pressemitteilung wurde bisher 417 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cynapsus Therapeutics Reports 2012 Financial Results and Highlights Key Developments
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cynapsus Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
